Congressional Testimony

• November 18, 2004
  Lester M. Crawford, D.V.M., Ph.D., Acting Commissioner of Food and Drugs
  Subject: FDA's Ongoing Efforts to Ensure the Safety, Effectiveness, and Availability of Influenza and Other Vaccines
  Before: Before the Committee on Energy and Commerce, United States House of Representatives
  
  
• November 18, 2004
  Sandra Kweder, M.D., Deputy Director, Office of New Drugs
  Subject: Vioxx and Drug Safety
  Before: Committee on Finance, United States Senate
  
  
• November 17, 2004
  Lester M. Crawford, D.V.M., Ph.D., Acting Commissioner of Food and Drugs
  Subject: FDA's Ongoing Efforts to Ensure the Safety, Effectiveness, and Availability of Influenza and Other Vaccines
  Before: Before the Committee on Government Reform, United States House of Representatives
  
  
• November 16, 2004
  Lester M. Crawford, D.V.M., Ph.D., Acting Commissioner of Food and Drugs
  Subject: FDA's Ongoing Efforts to Ensure the Safety, Effectiveness, and Availability of Influenza and Other Vaccines
  Before: Special Committee on Aging United States Senate
  
  
• October 5, 2004
  William Egan, Ph.D., Acting Director, Office of Vaccines Research and Review
  Subject: Regulation and oversight of vaccines in the United States
  Before: Subcommittee on Labor, Health and Human Services, Education and Related Agencies
  
  
• September 23, 2004
  Robert Temple, M.D., Director, Office of Medical Policy, Center for Drug Evaulation and Research
  Subject: Anti-depressant drugs for use in pediatric populations
  Before: Subcommittee on Oversight and Investigations, Committee on Energy and Commerce
  
  
• September 9, 2004
  Janet Woodcock, M.D., Acting Deputy Commissioner for Operations
  Subject: Pediatric Clinical Trials for Antidepressant Drug Products
  Before: Subcommittee on Oversight and Investigations, Committee on Energy and Commerce
  
  
• September 8, 2004
  William Egan, Ph.D., Office of Vaccines Research and Review, Center for Biologics Evaluation and Research
  Subject: Thimerosal in Vaccines
  Before: Subcommittee on Human Rights and Wellness, Committee on Government Reform
  
  
• July 22, 2004
  John M. Taylor, III, Associate Commissioner for Regulatory Affairs
  Subject: Importation of Prescription Drugs
  Before: Committee on Governmental Affairs
  
  
• July 14, 2004
  William K. Hubbard, Associate Commissioner for Policy and Planning
  Subject: Importation of Prescription Drugs
  Before: Committee on the Judiciary, United States Senate
  
  
• June 25, 2004
  Lester M. Crawford, D.V.M., Ph.D., Acting Commissioner of Food and Drugs
  Subject: Implementation of the Food Security Provisions of the Public Health Security and Bioterrorism Preparedness and Response Act
  Before: Committee on Energy and Commerce
  
  
• June 23, 2004
  Lester M. Crawford, D.V.M., Ph.D., Acting Commissioner of Food and Drugs
  Subject: The Law of Biologic Medicine
  Before: The Committee on the Judiciary
  
  
• June 8, 2004
  Robert E. Brackett, PH.D. Director Center for Food Safety and Applied Nutrition
  Subject: Dietary Supplement Safety Act: How is FDA Doing 10 Years Later
  Before: Committee on Governmental Affairs
  
  
• June 3, 2004
  Lester M. Crawford, D.V.M., Ph.D., Acting Commissioner of Food and Drugs
  Subject: HHS’s Role in Combating the Nation’s Obesity Epidemic
  Before: The Committee on Government Reform
  
  
• June 3, 2004
  Lynn C. Swann, Chairman, President’s Council on Physical Fitness and Sports, Office of Public Health and Science
  Subject: Combating the Obesity Epidemic
  Before: The Committee on Government Reform
  
  
  
• May 20, 2004
  John M. Taylor, Associate Commissioner for Regulatory Affairs
  Subject: Imported Drugs
  Before: Committee on Health Education, Labor and Pensions
  
  
• May 18, 2004
  Emanuel F. Petricoin III, Ph.D. Senior Investigator, Office of Cell, Tissue and Gene Therapies
  Subject: Conflict of Interest
  Before: The House Investigation and Oversight Subcommittee
  
  
• May 18, 2004
  Statement for the Record
  Subject: Comments on Ethics
  Before: Subcommittee on Oversight and Investigations
  
  
• May 18, 2004
  Steven Gutman, M.D., Director, Office of In Vitro Diagnostic Device Evaluation and Safety
  Subject: Adaltis Labotech device
  Before: Committee on Government Reform, U.S. House of Representatives
  
  
• May 13, 2004
  Richard Pazdur, M.D., Director, Division of Oncology Drug Products
  Subject: Harnessing Science: Advancing Care By AcceleratingThe Rate of Cancer Clinical Trial Participation
  Before: Committee on Government Reform, U.S. House of Representatives
  
  
• April 27, 2004
  William K. Hubbard, Associate Commissioner for Policy and Planning
  Subject: Importation of Prescription Drugs
  Before: Subcommittee on Healthcare and Subcommittee on International Trade, Committee on Finance
  
  
• April 1, 2004
  Robert J. Meyer, M.D., Director, Office of Drug Evaluation II, Center for Drug Evaluation, and Research
  Subject: FDA's Drug Approval Process
  Before: Subcommitte on Criminal Justice, Drug Policy and Human Resources, Committee on Government Reform.
  
  
• March 30, 2004
  Robert E. Bracket, Ph.D., Director, Center for Food Safety and Applied Nutrition
  Subject: Single Food Agency
  Before: Committee on Government Reform, Subcommittee on Civil Service and Agency Organization, United States House of Representatives.
  
  
• March 23, 2004
  Robert E. Brackett, Ph.D., Director, Center for Food Safety and Applied Nutrition
  Subject: Ten Years After the Implementation of DSHEA: The Status of Dietary Supplements in the United States.
  Before: Committee on Government Reform, Subcommittee on Human Rights and Wellness, United States House of Representatives.
  
  
• March 18, 2004
  William K. Hubbard, Associate Commissioner for Policy and Planning
  Subject: Internet Drug Sales
  Before: Committee on Government Reform, House of Representatives.
  
  
• March 11, 2004
  Daniel G. Schultz, M.D., Director, Office of Device Evaluation, Center for Devices and Radiological Health
  Subject: FDA’s implementation of Public Law (P.L.) 106-554 with respect to the labeling of condoms
  Before: Subcommittee on Criminal Justice, Drug Policy, and Human Resources Committee on Government Reform.
  
  
• March 11, 2004
  Dr. Mark B. McClellan, Commissioner of Food and Drugs
  Subject: Cost of Prescription Drugs
  Before: Committee on Commerce Science and Transportation United States Senate
  
  
• February 9, 2004
  Robert J. Meyer, M.D., Director, Office of Drug Evaluation II, Center For Drug Evaluation and Research
  Subject: FDA's Drug Approval Process and Role in Preventing Prescription Drug Abuse
  Before: U.S. House of Representatives, Committee on Government Reform, Subcommittee on Criminal Justice, Drug Policy and Human Resources.
  
  
• January 27, 2004
  Lester M. Crawford, D.V.M., Ph.D., Deputy Commissioner of Food and Drugs
  Subject: Bovine Spongiform Encephalopathy (BSE)
  Before: Committee on Agriculture, Nutrition and Forestry.